RxDoctor Payments Data

Wen Shen, MD

Nephrology · Washington, DCNPI 1629221551

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.2% of the total across 5 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Vantive US Healthcare LLC at 37.8% of the total. That places this record below the midpoint for nephrology clinicians in DC, where the typical reported total is $513.

$396in general payments, 2019–2025

Across 5 payments — averaging $79.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vantive US Healthcare LLC$150
  • Astellas Pharma US Inc$125
  • Mozarc Medical US LLC$96
  • Amgen$22
  • Travere Therapeutics, Inc.$3

What the payments were for

  • Food & beverage$39399%
  • Education$31%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$396 in reported general payments places this provider in the 45th percentile of 62 nephrology providers in District of Columbia.

See all nephrology providers in District of Columbia

Medicare billing

Part B allowed, 2024
$253,478
Medicare patients
504
Services billed
2,451

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin38$39,540
Sevelamer Carbonate85$22,096
Calcium Acetate83$6,262
Metolazone18$1,683
Torsemide46$1,463
Losartan Potassium136$1,455
Midodrine Hcl35$1,396
Carvedilol138$1,348
Potassium Chloride34$1,338
Hydralazine Hcl57$969
Amlodipine Besylate103$803
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst19$684
Nifedipine ErNifedipine14$636
Chlorthalidone46$630
Calcitriol25$541

Paid to pharmacies, not to this prescriber.

Other nephrology in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →